Pfizer Agrees to Purchase ReViral Ltd. For Up To $525-Million

Pfizer Inc., has now agreed for purchasing the respiratory antiviral drug producing company ‘ReViral Ltd.’ For a sum of 525 million dollars as the latest move of the company in the one-time overlooked field of the infectious disease.

The company ‘ReViral Ltd.’ Based in the United Kingdom has been developing the therapies for the respiratory syncytial virus, which has been a common lung ailment and Pfizer said that, the annual revenue can possibly reach 1.5 billion dollars, and the proposed transaction has been subject to the closing conditions, which is also including the receipt of the regulatory approvals as said by the company ‘Pfizer’.

After many years of neglecting the infectious disease among the large pharmaceutical companies, the company ‘Pfizer’ along with the competitors including Moderna and Johnson and Johnson has been seeing an increasing market for the novel corona virus vaccines, which are targeting the RSV that has particularly been dangerous to the young children, and the immunocompromised and the old people.

In March 2022, Pfizer has also received a breakthrough therapy designation for the company’s RSV vaccine candidate, which has currently been in the clinical trials. Annaliesa Anderson, chief scientific officer of bacterial vaccines and hospital unit of Pfizer said, currently, the treatment options for the RSV have been extremely limited and the focus is primarily on the supportive care.

Annaliesa Anderson also said that, the proposed acquisition of the pipeline of therapeutic candidates of ReViral has been complementary to their efforts for the purpose of advancing the first vaccine candidate for helping in protection against the harmful and dangerous disease.